Skin patches for generic drug delivery.
A clinical stage biotech redefining the skin’s potential as a therapeutic vector.
Key people at Avro Life Science.
Avro Life Science was founded by Shak Lakhani (Founder) and Keean Sarani (Founder).
Avro Life Science is a clinical-stage biotech company based in Waterloo, Ontario, specializing in transdermal drug delivery via innovative skin patches. Their proprietary polymer technology enables the passive delivery of small molecule generic drugs over a 1-7 day period, targeting populations such as children, the elderly, and patients with swallowing difficulties. This platform aims to replace traditional oral pills with medicated stickers, improving drug adherence and patient comfort. Avro is currently advancing toward clinical programs and establishing partnerships with pharmaceutical companies to co-develop and license their technology[1][2][3].
For an investment firm, Avro’s mission centers on transforming drug delivery through biomaterials innovation, focusing on sectors like biotechnology, pharmaceutical manufacturing, and medical devices. Their investment philosophy likely emphasizes early-stage, high-impact biotech ventures with scalable platform technologies. Avro’s impact on the startup ecosystem includes pioneering novel drug delivery methods and contributing to the growth of Canadian biotech innovation hubs such as the Velocity Incubator and Communitech network[2][3].
As a portfolio company, Avro builds transdermal skin patches for generic drug delivery, serving patients who face challenges with oral medication intake. The company solves the problem of drug administration compliance and safety, particularly for vulnerable groups like children and elderly patients. Avro has demonstrated growth momentum through successful funding rounds, accelerator participation (e.g., Bayer Grants4Apps), and progressing toward clinical trials[1][2][5].
Avro Life Science was founded in 2016 by Shakir Lakhani and Keean, both with backgrounds rooted in biomaterials and tissue engineering research. Shakir Lakhani began exploring biomaterials at age 15, conducting research at the University of Toronto’s tissue engineering lab. The idea for Avro emerged from the challenge of delivering drugs transdermally that were previously thought impossible to administer through the skin. Early traction included recognition in innovation awards and participation in prominent accelerators, which helped validate their technology and attract initial funding[1][3].
Avro Life Science rides the growing trend of non-invasive drug delivery systems and personalized medicine, addressing the limitations of oral drug administration. The timing is favorable due to increasing demand for patient-friendly therapies, aging populations, and advances in biomaterials engineering. Market forces such as rising healthcare costs and the need for improved medication adherence support the adoption of transdermal patches. Avro influences the broader ecosystem by pushing the boundaries of what drugs can be delivered through the skin, potentially reshaping pharmaceutical formulation and delivery paradigms[1][3][4].
Looking ahead, Avro Life Science is poised to advance its clinical pipeline and expand partnerships with pharmaceutical companies to commercialize its transdermal delivery platform. Trends such as digital health integration, personalized drug delivery, and expanding generic drug markets will shape their trajectory. Their influence may grow as they demonstrate clinical efficacy and regulatory approvals, potentially becoming a key player in the shift toward non-oral drug therapies. This aligns with their founding vision of replacing pills with skin patches, offering a more convenient and effective drug delivery method for diverse patient populations[1][3][5].
Key people at Avro Life Science.
Avro Life Science was founded by Shak Lakhani (Founder) and Keean Sarani (Founder).
